Geovax Labs Inc (GOVX) 0.1490 $GOVX
GeoVax Ebola Vaccine Proven Effective in Rodent Models
Marketwired - Tue Sep 08, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced today that its investigational Ebola vaccine candidate, GOVX-E301, provided 100 percent protection in guinea pigs and Syrian golden hamsters, two rodent models for Ebolavirus infections. The GOVX-E301 vaccine uses a recombinant modified vaccinia Ankara (MVA) vector to express non-infectious virus-like particles (VLPs) using genetic sequences from the 2014 Ebolavirus outbreak in West Africa. The studies were conducted in collaboration with, and funded in part by, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
GeoVax Reports 2015 Second Quarter Financial Results and Provides Corporate Update
Marketwired - Tue Aug 04, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced its financial results for the three and six months ended June 30, 2015 and provided the following corporate update.
Ebola Viral Infections Therapeutics Pipeline Review, H1 2015 - 30 Companies & 61 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdd37g/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Abivax S.A. - AmVac AG - AnGes MG, Inc. - Canopus BioPharma Incorporated - Crucell N.V. - Etubics Corporation - FIT Biotech Oy - GeoVax Labs, Inc. - GlaxoSmithKline plc - Hemispherx Biopharma, Inc. - Humabs BioMed SA - Immune Response BioPharma, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Kymab Limited - Medicago Inc. - Merck & Co., Inc. - Microbiotix, Inc. - Navigen Pharmaceuticals, Inc. - Novavax, Inc. - Peregrine Pharmaceuticals, Inc. - SignPath Pharma Inc - Sihuan Pharmaceutical Holdings Group Ltd. - SKAU Vaccines ApS - Tamir Biotechnology, Inc. - Tekmira Pharmaceuticals Corp. - Toyama Chemical Co., Ltd. - United Therapeutics Corporation - Vaxart, Inc. - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/qd...bola_viral
UTHR: 155.11 (+2.35), TKMR: 10.83 (+0.58), GSK: 40.26 (+0.02), INO: 7.34 (+0.23), NVAX: 10.00 (-0.10), MRK: 52.09 (-0.63)
GeoVax Receives Grant From NIH for HIV Vaccine Program
Marketwired - Wed Jul 01, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Small Business Innovative Research (SBIR) grant in support of its clade C HIV vaccine development program for Africa. The grant award of $299,585 is for the first year of a two-year project period beginning July 1, 2015.
AFRICAN LEADERSHIP MAGAZINE to Present Two Prestigious Awards to GeoVax and Dr. Robert McNally
Marketwired - Thu Jun 25, 4:45PM CDT
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that Robert McNally Ph.D., President & CEO, will receive the African Health Impact Award from The African Leadership Magazine during a ceremony to be held Friday, June 26th at 6:30 pm. He will also be inducted into the African Leadership Hall of Fame. The award recognizes GeoVax's significant ongoing role in the fight against HIV/AIDS and Ebola in Africa and its commitment to helping curb epidemics in the African continent.
GeoVax to Present at the LD Micro Invitational Conference
Marketwired - Wed May 27, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the LD Micro Invitational Conference on June 1, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr. Robert T. McNally, President and CEO, is scheduled to begin at 2:00PM PDT. Management will also be available during the conference for one-on-one meetings.
GeoVax to Present at the 2015 Marcum MicroCap Conference
Marketwired - Tue May 19, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 in New York City at the Grand Hyatt Hotel.
Global HIV Vaccine Market Future Outlook 2015
M2 - Mon May 18, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqfn9x/global_hiv) has announced the addition of the "Global HIV Vaccine Market Future Outlook" report to their offering. Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years. "Global HIV Vaccine Market Future Outlook" Report Highlights: - Introduction to HIV Vaccines - Issues Related to the Development of HIV Vaccines - Parameters for Successful Commercialization of HIV Vaccines - Global HIV Vaccines Market Opportunity Analysis - Global HIV Vaccine Clinical Pipeline by Company & Phase - Global HIV Vaccine Clinical Pipeline: 100 Vaccines - Majority Vaccine in Preclinical Phase: 42 Vaccines Companies Mentioned - AlphaVax - Antigen Express - Argo Therapeutics - Bionor Pharmaceuticals - Celldex Therapeutics - FIT Biotech - Crucell Pharmaceutical - GeneCure - Genetic Immunity - GenVec - GeoVax Labs - Glaxo Smithkline - Immune Response BioPharma - Inovio Pharmaceuticals - Novartis - Oncolys Biopharma - PaxVax - Profectus Biosciences - Sanofi - TVAX Biomedical For more information visit http://www.researchandmarkets.com/research/cqfn9x/global_hiv
INO: 7.34 (+0.23), CLDX: 15.45 (+0.53), NVS: 96.55 (+0.28)
GeoVax Reports 2015 First Quarter Financial Results and Provides Corporate Update
Marketwired - Wed May 13, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the three months ended March 31, 2015, and provided the following corporate update.
Liberia declared Ebola-free
Seeking Alpha - at Seeking Alpha - Sun May 10, 6:06AM CDT
BCRX: 12.94 (+0.47), VSR: 3.38 (unch), TKMR: 10.83 (+0.58), GSK: 40.26 (+0.02), NNVC: 1.02 (-0.02), JNJ: 92.93 (+0.21), INO: 7.34 (+0.23), CMRX: 52.22 (+3.17), APT: 2.10 (-0.01), HEB: 0.17 (unch), SRPT: 35.94 (+1.49), SMED: 9.00 (+0.60), NLNK: 51.03 (+1.84), PLX: 1.40 (-0.05), LAKE: 10.15 (+0.78), NSPH: 2.19 (-0.14)
GeoVax Path Forward Coming Into Focus
Jason Napodano, CFA - at Seeking Alpha - Wed Apr 22, 10:15AM CDT
GeoVax Enters Into Research Collaboration Agreement With the NIH for Ebola/Marburg Vaccines
Marketwired - Thu Apr 16, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced that it has entered into a Research Collaboration Agreement (the "Agreement"
with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for development of GeoVax's vaccines against Ebola and Marburg viruses.
GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine
Marketwired - Tue Apr 14, 8:02AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced its intention to pursue a dual pathway for advancing its preventive clade B HIV vaccine into pivotal human efficacy trials.
GeoVax Provides Details of Presentation at World Vaccine Congress
Marketwired - Thu Apr 09, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today provided details of the talk presented by its Chief Scientific Officer, Harriet L. Robinson, Ph.D., at the World Vaccine Congress in Washington, D.C. The title of her talk was, "Phase 2 Development of a Prophylactic HIV Vaccine."
GeoVax Labs Issues Letter to Shareholders
Marketwired - Mon Apr 06, 9:30AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and Marburg viruses, and HIV using its novel platform technology, has provided shareholders with an annual update letter. The letter is distributed in GeoVax's 2014 Annual Report to Shareholders mailed on April 2, and can be read in full by visiting the following link: http://www.geovax.com/investors.html
GeoVax Provides Update on Its HIV Vaccine Program
Marketwired - Wed Apr 01, 9:30AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate.
GeoVax's Chief Scientific Officer to Speak at World Vaccine Congress
Marketwired - Tue Mar 31, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced that Chief Scientific Officer Dr. Harriet L. Robinson, is invited to speak at the World Vaccine Congress to be held April 7-9, 2015 in Washington, DC. Dr. Robinson is scheduled to speak on April 8, 2015. The title of her talk is "Phase 2 Development of a Prophylactic HIV Vaccine."
GeoVax Appoints Industry Veteran to Its Board of Directors
Marketwired - Mon Mar 23, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg viruses, and HIV using its novel platform technology, today announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. This appointment brings the number of board members to six, four of whom are considered independent.
NVX: 14.89 (+0.07)
GeoVax Reports 2014 Year-End Financial Results
Marketwired - Fri Mar 20, 8:22AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2014, and provided the following corporate update.
GeoVax Provides Progress Report on Its Ebola Vaccine Program
Marketwired - Mon Jan 12, 8:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its unique vaccine delivery platform, today provided an update on its Ebola virus vaccine development program.
GeoVax Ebola Vaccine Proven Effective in Rodent Models
Marketwired - Tue Sep 08, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced today that its investigational Ebola vaccine candidate, GOVX-E301, provided 100 percent protection in guinea pigs and Syrian golden hamsters, two rodent models for Ebolavirus infections. The GOVX-E301 vaccine uses a recombinant modified vaccinia Ankara (MVA) vector to express non-infectious virus-like particles (VLPs) using genetic sequences from the 2014 Ebolavirus outbreak in West Africa. The studies were conducted in collaboration with, and funded in part by, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
GeoVax Reports 2015 Second Quarter Financial Results and Provides Corporate Update
Marketwired - Tue Aug 04, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced its financial results for the three and six months ended June 30, 2015 and provided the following corporate update.
Ebola Viral Infections Therapeutics Pipeline Review, H1 2015 - 30 Companies & 61 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdd37g/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Abivax S.A. - AmVac AG - AnGes MG, Inc. - Canopus BioPharma Incorporated - Crucell N.V. - Etubics Corporation - FIT Biotech Oy - GeoVax Labs, Inc. - GlaxoSmithKline plc - Hemispherx Biopharma, Inc. - Humabs BioMed SA - Immune Response BioPharma, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Kymab Limited - Medicago Inc. - Merck & Co., Inc. - Microbiotix, Inc. - Navigen Pharmaceuticals, Inc. - Novavax, Inc. - Peregrine Pharmaceuticals, Inc. - SignPath Pharma Inc - Sihuan Pharmaceutical Holdings Group Ltd. - SKAU Vaccines ApS - Tamir Biotechnology, Inc. - Tekmira Pharmaceuticals Corp. - Toyama Chemical Co., Ltd. - United Therapeutics Corporation - Vaxart, Inc. - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/qd...bola_viral
UTHR: 155.11 (+2.35), TKMR: 10.83 (+0.58), GSK: 40.26 (+0.02), INO: 7.34 (+0.23), NVAX: 10.00 (-0.10), MRK: 52.09 (-0.63)
GeoVax Receives Grant From NIH for HIV Vaccine Program
Marketwired - Wed Jul 01, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Small Business Innovative Research (SBIR) grant in support of its clade C HIV vaccine development program for Africa. The grant award of $299,585 is for the first year of a two-year project period beginning July 1, 2015.
AFRICAN LEADERSHIP MAGAZINE to Present Two Prestigious Awards to GeoVax and Dr. Robert McNally
Marketwired - Thu Jun 25, 4:45PM CDT
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that Robert McNally Ph.D., President & CEO, will receive the African Health Impact Award from The African Leadership Magazine during a ceremony to be held Friday, June 26th at 6:30 pm. He will also be inducted into the African Leadership Hall of Fame. The award recognizes GeoVax's significant ongoing role in the fight against HIV/AIDS and Ebola in Africa and its commitment to helping curb epidemics in the African continent.
GeoVax to Present at the LD Micro Invitational Conference
Marketwired - Wed May 27, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the LD Micro Invitational Conference on June 1, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr. Robert T. McNally, President and CEO, is scheduled to begin at 2:00PM PDT. Management will also be available during the conference for one-on-one meetings.
GeoVax to Present at the 2015 Marcum MicroCap Conference
Marketwired - Tue May 19, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 in New York City at the Grand Hyatt Hotel.
Global HIV Vaccine Market Future Outlook 2015
M2 - Mon May 18, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqfn9x/global_hiv) has announced the addition of the "Global HIV Vaccine Market Future Outlook" report to their offering. Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years. "Global HIV Vaccine Market Future Outlook" Report Highlights: - Introduction to HIV Vaccines - Issues Related to the Development of HIV Vaccines - Parameters for Successful Commercialization of HIV Vaccines - Global HIV Vaccines Market Opportunity Analysis - Global HIV Vaccine Clinical Pipeline by Company & Phase - Global HIV Vaccine Clinical Pipeline: 100 Vaccines - Majority Vaccine in Preclinical Phase: 42 Vaccines Companies Mentioned - AlphaVax - Antigen Express - Argo Therapeutics - Bionor Pharmaceuticals - Celldex Therapeutics - FIT Biotech - Crucell Pharmaceutical - GeneCure - Genetic Immunity - GenVec - GeoVax Labs - Glaxo Smithkline - Immune Response BioPharma - Inovio Pharmaceuticals - Novartis - Oncolys Biopharma - PaxVax - Profectus Biosciences - Sanofi - TVAX Biomedical For more information visit http://www.researchandmarkets.com/research/cqfn9x/global_hiv
INO: 7.34 (+0.23), CLDX: 15.45 (+0.53), NVS: 96.55 (+0.28)
GeoVax Reports 2015 First Quarter Financial Results and Provides Corporate Update
Marketwired - Wed May 13, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the three months ended March 31, 2015, and provided the following corporate update.
Liberia declared Ebola-free
Seeking Alpha - at Seeking Alpha - Sun May 10, 6:06AM CDT
BCRX: 12.94 (+0.47), VSR: 3.38 (unch), TKMR: 10.83 (+0.58), GSK: 40.26 (+0.02), NNVC: 1.02 (-0.02), JNJ: 92.93 (+0.21), INO: 7.34 (+0.23), CMRX: 52.22 (+3.17), APT: 2.10 (-0.01), HEB: 0.17 (unch), SRPT: 35.94 (+1.49), SMED: 9.00 (+0.60), NLNK: 51.03 (+1.84), PLX: 1.40 (-0.05), LAKE: 10.15 (+0.78), NSPH: 2.19 (-0.14)
GeoVax Path Forward Coming Into Focus
Jason Napodano, CFA - at Seeking Alpha - Wed Apr 22, 10:15AM CDT
GeoVax Enters Into Research Collaboration Agreement With the NIH for Ebola/Marburg Vaccines
Marketwired - Thu Apr 16, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced that it has entered into a Research Collaboration Agreement (the "Agreement"
with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for development of GeoVax's vaccines against Ebola and Marburg viruses. GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine
Marketwired - Tue Apr 14, 8:02AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced its intention to pursue a dual pathway for advancing its preventive clade B HIV vaccine into pivotal human efficacy trials.
GeoVax Provides Details of Presentation at World Vaccine Congress
Marketwired - Thu Apr 09, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today provided details of the talk presented by its Chief Scientific Officer, Harriet L. Robinson, Ph.D., at the World Vaccine Congress in Washington, D.C. The title of her talk was, "Phase 2 Development of a Prophylactic HIV Vaccine."
GeoVax Labs Issues Letter to Shareholders
Marketwired - Mon Apr 06, 9:30AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and Marburg viruses, and HIV using its novel platform technology, has provided shareholders with an annual update letter. The letter is distributed in GeoVax's 2014 Annual Report to Shareholders mailed on April 2, and can be read in full by visiting the following link: http://www.geovax.com/investors.html
GeoVax Provides Update on Its HIV Vaccine Program
Marketwired - Wed Apr 01, 9:30AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate.
GeoVax's Chief Scientific Officer to Speak at World Vaccine Congress
Marketwired - Tue Mar 31, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced that Chief Scientific Officer Dr. Harriet L. Robinson, is invited to speak at the World Vaccine Congress to be held April 7-9, 2015 in Washington, DC. Dr. Robinson is scheduled to speak on April 8, 2015. The title of her talk is "Phase 2 Development of a Prophylactic HIV Vaccine."
GeoVax Appoints Industry Veteran to Its Board of Directors
Marketwired - Mon Mar 23, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg viruses, and HIV using its novel platform technology, today announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. This appointment brings the number of board members to six, four of whom are considered independent.
NVX: 14.89 (+0.07)
GeoVax Reports 2014 Year-End Financial Results
Marketwired - Fri Mar 20, 8:22AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2014, and provided the following corporate update.
GeoVax Provides Progress Report on Its Ebola Vaccine Program
Marketwired - Mon Jan 12, 8:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its unique vaccine delivery platform, today provided an update on its Ebola virus vaccine development program.
